Immediate Therapeutics
Manufacturing · 1-10 Employees
View Company Info for Free
Overview
Phone Number
(908) 210-3347Website
www.immtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immediate Therapeutics
Immediate Therapeutics is focused on developing IMT-358, a first-in-class metabolic rescue therapy designed to prevent irreversible ischemic damage during acute ischemic emergencies. The therapy aims to stabilize cellular metabolism at the earliest phase of ischemia, addressing a critical unmet need in acute coronary syndromes and other time-sensitive ischemic conditions. IMT-358 is intended for rapid administration in emergency settings, aligning with clinical workflows where timely intervention is crucial. The company is advancing IMT-358 through Phase 3 planning, supported by clinical data from the NIH-funded IMMEDIATE-1 trial.Explore more
Immediate Therapeutics Org Chart
CL
Head of Market Access
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immediate Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Immediate Therapeutics launches new products
Immediate Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Immediate Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Immediate Therapeutics had a recent Job posting/layoffs
Check out if Immediate Therapeutics is spiking on competitors!
Check if Immediate Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Immediate Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Immediate Therapeutics
Recommended Actions
Reach out to Masked Content who joined Immediate Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Immediate Therapeutics
Compare insights from companies similar to Immediate Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Immediate Therapeutics
<$5M
1-10
Private
-
2020
BN
Bradley NewmanGlobal Head, Manufacuring & Supply Chain
Company Profile Activity
Activity Insights
Immediate Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immediate Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immediate Therapeutics.
Immediate Therapeutics Tech Stack
A closer look at the technologies used by Immediate Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immediate Therapeutics
Sign Up For FreeTo access detailed company insights
Immediate Therapeutics is focused on developing IMT-358, a first-in-class metabolic rescue therapy designed to prevent irreversible ischemic damage during acute ischemic emergencies. The therapy aims to stabilize cellular metabolism at the earliest phase of ischemia, addressing a critical unmet need in acute coronary syndromes and other time-sensit... Read More
